Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Makers Fight New Zealand’s Forced Switch To Indian Generics

This article was originally published in PharmAsia News

Executive Summary

Global drug makers are fighting a move by New Zealand to remove certain branded drugs from its drug formulary when generics become available. The country's Pharmaceutical Management Agency recently canceled coverage for AstraZeneca's Losec (omeprazole) for treating acid indigestion and reflux in favor of a generic from India's Dr. Reddy's Laboratories. Pharmac said the switch would save New Zealand $16.7 million over the next five years. AstraZeneca said the decision forces more than half a million New Zealanders to accept the generic or nothing, except for "a government-funded generic alternative produced in India." (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts